Obeticholic acid (DrugBank: Obeticholic acid)
4 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 20 | Adrenoleukodystrophy | 0 |
| 234 | Peroxisomal disease (except Adrenoleukodystrophy) | 0 |
| 265 | Lipodystrophy | 1 |
| 310 | Congenital anomalies syndrome | 0 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02430077 (ClinicalTrials.gov) | June 2016 | 24/4/2015 | Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients | Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients | Familial Partial Lipodystrophy | Drug: Obeticholic Acid;Drug: Placebo | University of Texas Southwestern Medical Center | NULL | Recruiting | 18 Years | 70 Years | All | 20 | Phase 2 | United States |